Editorially Independent content supported with advertising by Novartis and Alcon.


Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Reducing Treatment Intervals in Wet AMD

  Channels: Retina | Posted 10/22/2020

Arshad M. Khanani, MD, outlines the case of a patient whose wet AMD requires treatment every 4 to 6 weeks. The patient was diagnosed in 2010 and has been administered more than 60 doses of various anti-VEGF agents. The patient underwent therapy with brolucizumab (Beovu, Novartis), and began to experience improved vision and extended duration intervals. Hear a panel of experts discuss this case on the New Retina Radio miniseries The Art of Drug Choice: Wet AMD and the Latest Data.


1 / 4 Series: The Art of Drug Choice